Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting Taspase1 and the treatment of cancer.

Abstract: Devices, systems and methods detect latent HIV in a patient on anti-retroviral therapy (ART), the method comprising using optical scanning to identify in a cell sample of the patient Gag+ CD4 downregulated cells as in indication of latent HIV.

Abstract: Disclosed are compositions comprising a mesothelin protein and an adjuvant. Disclosed are compositions comprising a mesothelin protein, an adjuvant, and a second adjuvant. In some instances the adjuvant is cyclic dinucleotides (CDNs). Disclosed are compositions comprising a mesothelin protein, CDNs, and a squalene based oil-in-water emulsion. Disclosed are methods of treating cancer comprising administering to a subject a composition or vaccine, wherein the composition or vaccine comprises a mesothelin protein, an adjuvant, and a second adjuvant.

Abstract: Embodiments in accordance with the present disclosure include apparatuses, devices, and methods. For example, a method is directed to method exposing immobilized white blood cells from a blood sample to an antigen. And, scanning the immobilized white blood cells and, therefrom, identify and isolate white blood cells from among the immobilized white blood cells that produce an antibody in response to the exposure to the antigen.

Abstract: Devices, systems and methods detect latent HIV in a patient on anti-retroviral therapy (ART), the method comprising using optical scanning to identify in a cell sample of the patient Gag+CD4 downregulated cells as in indication of latent HIV.

Abstract: The invention provides methods and compositions for inhibiting tumor growth in a mammal. The methods comprise administering to the mammal a synergistic combination of (7?)-21-[4-[(Diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate and a synergistic chemotherapeutic drug. The combination of the compounds more than additively inhibits growth of tumor cells.

Abstract: The disclosure provides compositions and methods for treating multiple myeloma. In some embodiments, the compositions comprise (E)-3-hydroxy-21-[2?-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutical carrier.

Abstract: The disclosure provides compositions and methods for treating multiple myeloma. In some embodiments, the compositions comprise (E)-3-hydroxy-21-[2?-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutical carrier.

Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.